Hepatobiliary complications of inflammatory bowel disease

Current Gastroenterology Reports

Volumn 13, Issue 5, 2011, Pages 495-505

  Lichtenstein, David R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune cholangiopathy; Cholangitis; Cholestasis; Colorectal cancer; Dominant stricture; ERCP; Gallbladder cancer; Hepatobiliary complications; IgG4 associated sclerosing cholangitis; Inflammatory bowel disease; Liver biopsy; Liver transplantation; MRCP; Osteopenia; Osteoporosis; Overlap syndrome; Primary sclerosing cholangitis; Pruritis; Secondary sclerosing cholangitis; Small duct PSC; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLCHICINE; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN G4; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID; NALMEFENE; NALOXONE; NALTREXONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; ONDANSETRON; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; RIFAMPICIN; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; URSODEOXYCHOLIC ACID; VITAMIN D;

ALPHA TOCOPHEROL DEFICIENCY; AUTOIMMUNE HEPATITIS; BALLOON DILATATION; BILE DUCT BYPASS; BILE DUCT CARCINOMA; CANCER RISK; CHOLANGIOGRAPHY; CHOLECYSTECTOMY; CHOLELITHIASIS; CHOLESTASIS; CHRONIC HEPATITIS; COLON CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; ENDOSCOPIC SURGERY; ENTERITIS; HEPATOBILIARY DISEASE; HUMAN; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOGRAPHY; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINOL DEFICIENCY; REVIEW; STEATORRHEA; STENT; SURVIVAL RATE; SYMPTOM; VITAMIN D DEFICIENCY;

AVITAMINOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLESTASIS; CONSTRICTION, PATHOLOGIC; END STAGE LIVER DISEASE; GALLBLADDER DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; OSTEOPOROSIS; PRURITUS;

EID: 80755182321     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0213-9     Document Type: Review

References (96)

1. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 1999;28:491-513. (Pubitemid 29306490)
2. Bambha K et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125:1364-9. (Pubitemid 37409756)
3. Lindkvist B, Benito de Valle M, Gullberg B, et al. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571-7.
4. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology. 2004;126:1929-30. (Pubitemid 38736362)
5. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042-9. (Pubitemid 46705300)
6. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319-23.
7. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195-9.
8. Chapman R, Fevery J, Kalloo A, et al. AASLD Practice guidelines: diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78. This is the current AASLD recommendations of the preferred approaches to the diagnosis and therapy of PSC. The guideline discusses variant forms of PSC, pharmacologic and surgical treatment of PSC, and complications related to dominant strictures and cholangiocarcinoma.
9. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107-14. (Pubitemid 46072050)
10. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-7.
11. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688-94.
12. Dickson ER, Murtaugh PA, Wiesner RH, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 1992;103:1893-901.
13. Rudolph G, Gotthardt D, Kloters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149-55.
14. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology. 1997;25:1049-53. (Pubitemid 27199926)
15. Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut. 1992;33:657-62.
16. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006;4:514-20.
17. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc. 2006;64:219-23. (Pubitemid 44062484)
18. Dave M, Elmunzer BJ, Dwamena BA, Higgins PD. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010;256:387-96. MRC is the preferred imaging technology for confirming the diagnosis of PSC and has supplanted ERCP due to the invasive nature and potential for complications with ERCP.
19. Banerjee S, Shen B, Shen TH, et al. ASGE Standards of Practice Committee. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc. 2008;67:791-8.
20. Olsson R, Hagerstrand I, Broome U, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J Clin Pathol. 1995;48:933-5.
21. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol. 2003;98:1155-8. (Pubitemid 36733781)
22. Kim WR, Ludwig J, Lindor KD. Variant forms of cholestatic diseases involving small bile ducts in adults. Am J Gastroenterol. 2000;95:1130-8. (Pubitemid 30263502)
23. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis. 1991;11:11-7.
24. Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975-80. (Pubitemid 351451987)
25. Angulo P, Maor-Kendler Y, Lindor K, et al. Small-duct primary sclerosing cholangitis: a long term follow-up study. Hepatology. 2002;35:1494-500. (Pubitemid 34966904)
26. Charatcharoenwitthaya P, Angulo P, Enders FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008;47:133-42. (Pubitemid 351171050)
27. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706-15. A study of 53 patients with IgG4-associated cholangitis (IAC) describing the clinical presentation, serologic markers, imaging characteristics and treatment response. (Pubitemid 351312724)
28. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070-5. (Pubitemid 44337633)
29. Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008;28:209-20. (Pubitemid 351861961)
30. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516-22. (Pubitemid 41032356)
31. Shi J, Li Z, Zeng X, et al. Ursodeoxycholic acid in primary sclerosing cholangitis: metaanalysis of randomized controlled trials. Hepatol Res. 2009;39:865-73.
32. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36:525-31. (Pubitemid 34977162)
33. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-72. (Pubitemid 41597389)
34. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14. A randomized, placebocontrolled trial indicating potential harmful effects on clinical course of PSC with high dose UDCA therapy.
35. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol advance online publication 2011; doi:10.1038/ajg.2011.156. Long-term use of high-dose UDCA was associated with a 4.4 fold increased risk of colorectal neoplasia in patients with UC and PSC.
36. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.
37. Mela M, Mancuso A, Burroughs AK. Review article: pruritis in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-70. (Pubitemid 36459598)
38. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180-8. Osteoporosis (T-score less than ?2.5) was found in 15% of patients and occurred 23.8-fold (95% confidence interval, 4.6-122.8) more frequently in those with PSC than expected from a matched population. By multivariate analysis, age 54 years or older (odds ratio [OR], 7.8; 95% CI, 3.3-18.3), body mass index ≤24 kg/m(2) (OR, 4.9; 95% CI, 1.9-12.6), and inflammatory bowel disease for ≥19 years (OR, 3.6; 95% CI, 1.5-8.4) correlated with the presence of osteoporosis.
39. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46:1271-8.
40. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 2003;125:937-40.
41. Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003;38:856-65. (Pubitemid 36613356)
42. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis:a randomized placebo-controlled trial. Hepatology. 2005;42:762-71. (Pubitemid 41401113)
43. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:502-8. (Pubitemid 38524130)
44. Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151-6. (Pubitemid 34146420)
45. MacCarty RL, LaRusso NF, May GR, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology. 1985;156:43-6. (Pubitemid 15226202)
46. Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc. 1991;37:38-43.
47. Lee JG, Schutz SM, England RE, et al. Endoscopic therapy of sclerosing cholangitis. Hepatology. 1995;21:661-7.
48. Van Milligen de Wit AW, van Bracht J, Rauws EA, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1996;44:293-9. (Pubitemid 26318331)
49. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308-12. (Pubitemid 32207314)
50. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96:1059-66. (Pubitemid 32319137)
51. Ponsioen C, Lam K, van Milligen de Wit A, et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. 1999;94:2403-7. (Pubitemid 29420664)
52. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 1997;26:560-6. (Pubitemid 27112721)
53. Gluck M, Cantone NR, Brandabur JJ, et al. A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42:1032-9.
54. Van Milligen de Wit AW, Rauws EA, van Bracht J, et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1997;46:344-7. (Pubitemid 27459273)
55. Ahrendt SA, PittHA, KalloAK, et al. Primary sclerosing cholangitis. Resect, dilate, or transplant? Ann Surg. 1998;227:412-23.
56. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol. 2003;38:1176-83. (Pubitemid 37518603)
57. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 1997;225:472-83. (Pubitemid 28079096)
58. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma:is transplantation an option? For whom? J Hepatol. 2007;47:455-9.
59. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2002;8:575-81. (Pubitemid 34752702)
60. Cholongitas E, Shusang V, Papatheodoridis GV, et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008;14:138-43. (Pubitemid 351267268)
61. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14:181-5. (Pubitemid 351267274)
62. Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after liver transplantation: a review. Dig Surg. 2008;25:245-57.
63. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321-7. (Pubitemid 34194790)
64. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790-4. (Pubitemid 19057601)
65. Loftus Jr EV et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-6. (Pubitemid 40007225)
66. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol. 2009;44:46-55.
67. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50:158-64. A total of 211 patients with PSC were included, 143 (68%) were male and 126 (60%) had IBD. The risk of cholangiocarcinoma after 10 years was 9%. In patients with concomitant IBD the 10-year and 20-year risks for CRC were 14% and 31%, respectively.
68. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis:a meta-analysis. Gastrointest Endosc. 2002;56:48-54. (Pubitemid 41115048)
69. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, et al. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:52-6.
70. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746-74.
71. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-21. (Pubitemid 40439686)
72. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in Parameters Committee. Am J Gastroenterol. 2004;99:1371-85.
73. Pardi DS, Loftus Jr EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-93. (Pubitemid 36389790)
74. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95. (Pubitemid 32096335)
75. Dvorchik I, Subotin M, Demetris AJ, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35:380-4. (Pubitemid 34106378)
76. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003;75:1983-8. (Pubitemid 36793279)
77. Brandt DJ, MacCarty RL, Charboneau JW, LaRusso NF, Wiesner RH, Ludwig J. Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol. 1988;150:571-4. (Pubitemid 18075395)
78. Buckles DC, Lindor KD, Larusso NF, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol. 2002;97:1138-42. (Pubitemid 34478111)
79. Lewis JT, Talwalkar JA, Rosen CB, et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis:evidence for a metaplasia-dysplasiacarcinoma sequence. Am J Surg Pathol. 2007;31:907-13. (Pubitemid 47165145)
80. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008;48:598-605.
81. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523-6. (Pubitemid 38524134)
82. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123-35. (Pubitemid 47512534)
83. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31:7-11. (Pubitemid 30033681)
84. Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology. 2008;47:90-6. (Pubitemid 351171045)
85. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205-11. (Pubitemid 35189610)
86. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108:865-9.
87. Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum Ca19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc. 1993;68:874-9.
88. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734-40. (Pubitemid 41203674)
89. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106-17. A study looking at the value of CA 19-9 combined with cross-sectional liver imaging and cholangiography with cytologic examination to diagnose cholangiocarcinoma in patients with PSC.
90. Ferrari Junior AP, Lichtenstein DR, Slivka A, et al. Brush cytology during ERCP for the diagnosis of biliary and pancreatic malignancies. Gastrointest Endosc. 1994;40:140-5. (Pubitemid 24129187)
91. Rumalla A, Baron TH, Leontovich O, et al. Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis. Mayo Clin Proc. 2001;76:29-33.
92. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy. 1999;31:305-9. (Pubitemid 29229369)
93. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56:40-7. (Pubitemid 41115047)
94. Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy. 2006;38:665-9. (Pubitemid 44044391)
95. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology. 2006;131:1064-72. (Pubitemid 44498705)
96. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-8. discussion 458-461.